

Supplementary Material

Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: a retrospective cohort study

Nima Iranpour^A, Gregory J. Dore^A, Marianne Martinello^A, Gail V. Matthews^A, Jason Grebely^A and Behzad Hajarizadeh^{A,B}

^AThe Kirby Institute, Wallace Wurth Building, UNSW Sydney, NSW 2051, Australia.

^BCorresponding author. Email: bhajarizadeh@kirby.unsw.edu.au

Table 2. DAA regimens listed on the Pharmaceutical Benefits Scheme in Australia, by 2017

Treatment regimen	Month and year of PBS listing	Eligible HCV genotypes	Eligible durations
Sofosbuvir/ledipasvir ± ribavirin	March 2016	Genotype 1	8, 12 and 24 weeks
Sofosbuvir + daclatasvir ± ribavirin	March 2016	Genotypes 1 and 3	12 and 24 weeks
Sofosbuvir + ribavirin	March 2016	Genotype 2	12 weeks
Sofosbuvir + pegylated interferon + ribavirin	March 2016	Genotypes 1, 3, 4, 5 and 6	12 weeks
Paritaprevir/ritonavir/ombitasvir + dasabuvir ± ribavirin	May 2016	Genotype 1	12 and 24 weeks
Elbasvir/grazoprevir	January 2017	Genotypes 1 and 4	12 and 16 weeks
Sofosbuvir/velpatasvir ± ribavirin	August 2017	Genotypes 1 to 6	12 weeks